focus -WSS

focus

author：fashion 2025-10-02 16:18:55 - browse：3892

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medical mystery: When a cough is not just a cough

hotspot

WSS

Industry veterans launch new biotech VC with $310M

Appeals court upholds limits to abortion pill

BioAge raises $170M for combination therapy with Zepbound

Diversity in medical illustrations gets boost from Chidiebere Ibe

2024 GOP presidential candidates spar over abortion in debate

Medicare threatens to cut off funding for HCA's Mission hospital

leisure time

focus

knowledge

Jerome Adams on the need for new antivirals for Covid

The dental labor crisis is a moment of opportunity

Psychedelics group wrestles with new pharma identity

Australia’s approach to dialysis celebrates life

Medical records are filled with copy

In science, is the line between industry and academia shifting?

State Dept. review finds Biden bears some blame for Afghanistan failures

A disappointing year of Humira biosimilars

Peter Hotez and the public health issue of online harassment

Complete sequence of Y chromosome published for first time

entertainment

Senators start work on Medicare physician payment reform

Diversity in medical illustrations gets boost from Chidiebere Ibe

Neuroscience startup Neumora files for IPO

Complete sequence of Y chromosome published for first time

To avoid data mishandling cases, universities eye AI and other tools

Study finds new variant for Parkinson’s in African populations

leisure time

hotspot

focus

explore